

Bacterial Isolation and Antibiotic Resistance Patterns in Urinary Tract Infections: A Focus on Fosfomycin Resistance in *E. coli*

Shramima Nasrin*¹, Abul Bashar Md Mahbubul Haque², Rifat Zaman³, Sohel Uddin⁴, Elora Parveen⁴, MA Munnaf Sarker⁵, Mosiur Rahman⁶, Abu Yousuf²

¹ Department of Microbiology, Rajshahi Medical College Hospital, Rajshahi

² Department of Neurology, Rajshahi Medical College, Rajshahi

³ Department of Medicine, Kumudini Women's Medical College Hospital, Tangail

⁴ Department of Neuromedicine, Rajshahi Medical College Hospital, Rajshahi

⁵ Department of Medicine, Rajshahi Medical College Hospital, Rajshahi

⁶ Department of Medicine, Rajshahi Medical College Hospital, Rajshahi



Citation:

Nasrin S., Haque ABMM, Zaman R, Uddin S, Parveen E, Sarker MAMM, Rahman M, Yousuf A; Bacterial Isolation and Antibiotic Resistance Patterns in Urinary Tract Infections: A Focus on Fosfomycin Resistance in *E. coli*. Journal of Teachers Association. 2025;38(2): 28-36

Article History:

Received: 03.02.2025

Accepted: 18.04.2025

Published: 01.06.2025



Copyright © 2025 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0

International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

ABSTRACT: *Background:* Urinary tract infections (UTIs) are one of the most common bacterial infections globally, with increasing antimicrobial resistance (AMR) posing a significant challenge to effective treatment. *Objective:* This study aims to isolate and identify bacterial uropathies, assess their antimicrobial susceptibility patterns, and determine the presence of Fosfomycin-resistant *E. coli* strains in a tertiary care hospital in Rajshahi, Bangladesh. *Methods:* A descriptive cross-sectional study was conducted at Rajshahi Medical College Hospital, Bangladesh, from January to December 2019. A total of 285 urine samples were collected from clinically suspected UTI patients. Bacterial identification was performed using culture, Gram staining, and biochemical tests. Antimicrobial susceptibility testing was conducted using the Kirby-Bauer disk diffusion method, following Clinical and Laboratory Standards Institute (CLSI) guidelines. Fosfomycin-resistant *E. coli* isolates were subjected to polymerase chain reaction (PCR) for the detection of the *fosA3* gene. Data analysis was performed using SPSS version 24.0. *Result:* Among 285 participants, 53.68% (153/285) were culture positive, with *E. coli* (60.49%) being the most prevalent isolate. Gram-negative bacteria accounted for 83.95% of isolates. *E. coli* exhibited high resistance to Amoxiclav (79.59%) and Ciprofloxacin (56.12%), while showing highest sensitivity to Imipenem (88.78%). Fosfomycin resistance was detected in only 2 *E. coli* isolates. Other uropathogens such as *Klebsiella* spp., *Pseudomonas* spp., and *Proteus* spp. exhibited high resistance to cephalosporins but remained sensitive to carbapenems. Among Gram-positive bacteria, *Staphylococcus aureus* was fully susceptible to Levofloxacin, while Coagulase-negative *Staphylococci* (CoNS) showed 100% sensitivity to Linezolid. PCR analysis confirmed the presence of the *fosA3* gene in the two Fosfomycin-resistant *E. coli* isolates. *Conclusion:* The study highlights *E. coli* as the dominant UTI pathogen with significant resistance to β -lactams and fluoroquinolones, reinforcing the importance of carbapenems and Fosfomycin as viable treatment options.

Keywords: Urinary Tract Infection, Antimicrobial Resistance, *E. Coli*, Fosfomycin, *FosA3* Gene, Multidrug Resistance.

Article at a glance:

Study Purpose: To isolate UTI-causing bacteria and assess antibiotic resistance, with a focus on Fosfomycin-resistant *E. coli* strains

Key findings: *E. coli* was the most common UTI pathogen, showing high resistance to Amoxiclav and Ciprofloxacin, but sensitivity to Imipenem.

Newer findings: Fosfomycin resistance in *E. coli* was rare, and the *fosA3* gene was detected, suggesting continued usefulness of Fosfomycin in MDR cases.

Abbreviations: UTI – Urinary Tract Infection, AMR – Antimicrobial Resistance, MDR – Multidrug-Resistant, PCR – Polymerase Chain Reaction

INTRODUCTION

Urinary tract infections (UTIs) are among the most common bacterial infections encountered in

clinical practice, affecting millions of individuals worldwide. They range from uncomplicated cystitis to severe cases involving bacteremia, leading to significant morbidity and healthcare burden.¹ UTIs

are prevalent in both community and hospital settings, often associated with recurrent infections that impact patients' quality of life.²⁻³ According to global prevalence study, 404.61 million cases and 236,790 deaths were estimated in 2019. 2.4 times growth in deaths from 1990 to 2019 was observed.⁴ The prevalence of UTI varies across regions: 42% in Bangladesh, 34.6% in India and 22.7% in Ethiopia.^{5,6,7} Bacteria are the primary etiological agents of UTIs, with Gram-negative bacteria accounting for 80-85% and Gram-positive bacteria for 15-20% of cases.⁸ Among these, *Escherichia coli* remains the most frequently isolated uropathogen, responsible for 85% of community-acquired and 50% of hospital-acquired infections.⁹ Other significant pathogens include *Klebsiella pneumoniae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Enterobacter spp.*, *Enterococcus spp.*, and *Staphylococcus aureus*.⁹ The risk factors influencing UTI prevalence include gender, age, diabetes, urinary catheterization, previous antibiotic therapy, and congenital urinary tract abnormalities.¹⁰ UTIs are significantly more common in females, with reported prevalence rates of 63.39% in Bangladesh and 65% in India.^{11,12} The widespread misuse of antibiotics—including indiscriminate prescriptions, improper dosing, self-medication, and over-the-counter sales—has contributed to rising resistance levels, particularly in developing countries where inadequate healthcare infrastructure and poor hygiene practices exacerbate the problem.¹³ The World Health Organization has declared AMR a global threat, emphasizing the need for strict antimicrobial surveillance and antibiotic stewardship programs.¹⁴ Due to the increasing resistance against commonly used antibiotics like Penicillin, Cephalosporins (Cefotaxime, Ceftriaxone, Ceftazidime, Cefuroxime, Cefepime), Fluoroquinolones (Ciprofloxacin, Levofloxacin), and Macrolides (Azithromycin), treatment options for multidrug-resistant (MDR) uropathogens have become limited. Carbapenems, Colistin, and Fosfomycin are often the last resort for treating these infections.¹⁵ Fosfomycin, a phosphonic acid derivative first discovered in 1969, has resurfaced as an effective treatment option, particularly for uncomplicated UTIs.¹⁶ Studies indicate that 98–99% of ESBL-producing uropathogens remain susceptible to Fosfomycin.¹⁷ The prevalence of Fosfomycin resistance varies geographically, with limited data available, especially in Bangladesh and other developing nations. Given the limited availability of novel antimicrobials, re-evaluating older antibiotics

like Fosfomycin presents an opportunity to counter rising drug resistance. Despite its broad-spectrum activity, single-dose efficacy, low resistance rates, and cost-effectiveness, Fosfomycin remains underutilized in many regions, including Bangladesh. This study aims to isolate and identify bacterial uropathogens and assess their antimicrobial susceptibility to better understand Fosfomycin resistance trends.

Aims and Objectives

To isolate and identify bacterial uropathogens along with their susceptibility pattern and determination of Fosfomycin resistant *E. coli* strain in a tertiary care hospital in Rajshahi.

MATERIALS AND METHODS

A descriptive type of cross-sectional study was conducted at the Department of Microbiology, Rajshahi Medical College, Rajshahi, Bangladesh, with molecular analysis performed at the Molecular Biology and Protein Science Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi. The study was carried out from January 2019 to December 2019, including adult patients of both sexes with clinically suspected urinary tract infections (UTIs) attending inpatient and outpatient departments of Rajshahi Medical College Hospital. Ethical clearance was obtained from the Institutional Review Board (IRB) of Rajshahi Medical College, and additional approvals were secured from the hospital authorities before study initiation. The sample size was determined using Cochran's formula, and 285 urine samples were collected using a purposive sampling technique. Midstream urine samples were obtained from non-catheterized patients, while urine from catheterized patients were collected aseptically using a sterile syringe. Patients were included in the study if they presented with UTI symptoms such as dysuria, urgency, and frequency. Exclusion criteria included patients on antibiotic therapy at the time of sample collection, those with evidence of hematuria or chyluria, and those unwilling to participate in the study. Informed written consent was obtained from all participants before sample collection. A structured, pre-tested questionnaire was used to collect demographic and clinical information from the participants. Microscopic examination of urine was performed by centrifuging 5 ml of each sample at 3000 rpm for 5 minutes, followed by wet mount examination of the sediment under a microscope at 10X and 40X magnifications. Urine samples were

cultured on chromogenic UTI agar, MacConkey agar, blood agar, and nutrient agar using a calibrated loop method and incubated at 37°C for 18-20 hours. Bacterial identification was performed based on colony morphology, Gram staining, and standard biochemical tests. Antimicrobial susceptibility testing was conducted using the Modified Kirby-Bauer disk diffusion method on Mueller-Hinton agar, following Clinical and Laboratory Standards Institute (CLSI) guidelines. Gram-positive bacteria were tested against amoxiclav, oxacillin, vancomycin, cefuroxime, gentamicin, amikacin, ciprofloxacin, azithromycin, linezolid, ceftriaxone, nitrofurantoin, levofloxacin, imipenem, meropenem, and fosfomycin. Gram-negative bacteria were tested against amoxiclav, cefuroxime, ceftazidime, gentamicin, amikacin, ciprofloxacin, azithromycin, fosfomycin, ceftriaxone, nitrofurantoin, meropenem, and imipenem. Zone sizes were measured and categorized as sensitive, intermediate, or resistant according to CLSI (2017) guidelines. Fosfomycin-resistant *E. coli* isolates were preserved at -20°C in trypticase soy broth with 20% glycerol. Molecular detection of the *fosA3* gene was

performed using conventional polymerase chain reaction (PCR). Plasmid DNA extraction was carried out using a Promega plasmid DNA isolation kit, followed by amplification using specific primers. PCR products were analyzed via agarose gel electrophoresis and visualized under a UV illuminator. Data were analyzed using SPSS version 24.0, and results were presented in tables, charts, and descriptive statistics.

RESULTS

Sociodemographic Characteristics of Participants

The study included 285 participants, with the majority (30.18%) aged between 21-30 years, followed by 26.6% in the 31-40 years category. A smaller proportion (5.2%) were aged 51 years or older. The participants were predominantly female (65.26%). Most of the participants were married (75.8%), suggesting that the study population had a significant proportion of adults who might be engaged in household or occupational responsibilities that could influence bacterial infections (Table 1).

Table I: Distribution Of the Participants According to Sociodemographic Characteristics (n=285)

Variables	Frequency	Percentage
Age		
≤20	62	21.75
21-30	86	30.18
31-40	76	26.6
41-50	46	16.1
≥51	15	5.2
Sex		
Female	186	65.26
Marital status		
Married	216	75.8

Distribution of Bacterial Isolates

The bacterial isolates were distributed as culture negative (132, 46.32%) and culture positive

(153, 53.68%). Among the culture positive isolates, 144 (94.1%) were single isolates and 9 (5.88%) were multiple isolates. (Figure 1).




Figure 1: Distribution of the Participants According to Types of Bacterial Isolates (n=285)

Gram Staining of the Organisms

The distribution of bacterial isolates according to Gram staining showed higher prevalence of gram negative (136, 83.95%) organisms. (Figure 2)




Figure 2: Distribution of the Participants According to Gram Staining of the Organisms (n=285)

Antimicrobial sensitivity and resistant pattern

E. coli showed the highest sensitivity towards Imipenem (88.78%) and highest resistance to Amoxiclav (79.59%). Fosfomycin resistance was shown in only 2 isolates of *E. coli*. But nearly 100% sensitivity against rest of the pathogens. *Klebsiella* had the highest sensitivity to Meropenem (85.71%) and highest resistance to ceftriaxone (71.43%). *Pseudomonas spp.* and *Proteus spp.* had highest resistance against amoxiclav (83.3%, 66.7%) and both

showed sensitivity against carbapenems. Although *Enterobacter spp.* had resistance (83.3%) towards Amoxiclav but remains 100% sensitive towards Amikacin. *Coagulase-negative Staphylococci* showed 100% sensitivity towards Linezolid. All *Staphylococcus aureus* isolates were sensitive to Levofloxacin and complete resistance to Gentamycin was observed. All *Enterococcus spp.* isolates were fully susceptible to Meropenem (table 2).

Table 2: Distribution of the Participants According to Antimicrobial Susceptibility and Resistance Pattern

Antibiotics	<i>E. coli</i> (98)	<i>Klebsiella spp.</i> (14)	<i>Pseudomonas spp.</i> (12)	<i>Proteus</i> (6)	<i>Enterobacter spp.</i> (6)	CoNS spp. (7)	<i>Staph aureus</i> (6)	<i>Enterococcus</i> (9)
Amikacin								
Sen						3	4	6

Int						1		
Res						3	2	3
Amoxiclav								
Sen	16	3	2	2	1	2	3	5
Int	4	3				1		2
Res	78	8	10	4	5	4	3	2
Azithromycin								
Sen	64	10		4	4	2	4	6
Int	4	1						1
Res	30	3		2	2	5	2	2
Cefepime								
Sen	79							
Int	1							
Res	18							
Ceftazidime								
Sen	40	5		2	3			8
Int	2	1						
Res	56	8		4	3			1
Ceftriaxone								
Sen	37	3	6	3	4	2	3	8
Int	5	1	2			1	3	
Res	56	10	4	3	2	4		1
Cefuroxime								
Sen		3	7		4			
Int		1	2		1			
Res		10	3		1			
Cefotaxime								
Sen	32			2	3			
Int	1							
Res	65			4	3			
Ciprofloxacin								
Sen	38	5	7	4	5	2	1	3
Int	3	2	2			1	1	
Res	57	7	3	2	1	4	4	6
Co-trimoxazole								
Ses	22	5	4	4	1			
Int	7	2	2		1			
Res	72	7	7	2	4			
Gentamycin								
Sen	63	10	9	4	4	4		6
Int	2	1	1		1	1		
Res	33	3	2	2	1	2	6	3
Levofloxacin								
Sen	49	10	6	4		5	6	
Int	3	2	2					
Res	46	2	4	2		2		
Linezolid								
ses						7	6	
Meropenem								
Sen	85	12	9	6	6			
Inter	4							

Res	9	2	3					
Imipenem								
Sen	87	12	10	6	6			9
Int	4							
Res	7	2	2					
Piperacillin/Tazobactam								
Sen			10					
Int			1					
Res			1					
Vancomycin								
Sen						7	6	8
Int								
Res								1
Oxacilin								
Ses						5	6	6
Int						1		
Res						1		3
Nitrofurantoin								
Sen	70	10	10	6	5		5	6
inter	7	1						
Res	21	3	2		1		1	3
Fosfomycin								
Sen	96	13	11	6	6	6	6	9
Int		1	1				1	
Res	2							

DISCUSSION

Antimicrobial resistance poses a major challenge to effective treatment, especially for UTIs, leading to increased mortality, morbidity, and healthcare costs. Key contributors in developing countries include irrational antibiotic use, lack of awareness, unauthorized sales, limited healthcare access, weak surveillance, and antimicrobial use in livestock and agriculture.¹⁸ A total of 285 urine samples were collected from clinically suspected urinary tract infections cases in the present study; where majority of the participants (86, 30.18%) were within the age group 21-30 years with female predominance (65.26%). Even though age prevalence of UTI varies greatly depending on hygiene practice, sexual activity, reproductive changes and hormonal changes, several literatures found similar age range to be prevalent among UTI patients.¹⁹⁻²¹ Female predominance in UTI was supported by a couple of national and international studies.^{11,21-23} The reason behind this high prevalence of UTI in female is due to short urethra, close proximity of the urethra with anus, deferred voiding habit, wearing tight undergarments, use of diaphragms and spermicides, long duration tampons use, hormonal effect, host

factor such as changes in normal vaginal flora, cleaning perineum forward from the anus to the vulva. Like the present study, UTI among married persons were more common; possibly because lack of interest hygiene after and before sexual activity and use of certain contraceptives.^{20,24-26} In present study 191 urine samples 153 (53.68%) samples were culture positive, whereas 132 (46.32%) samples were culture negative. Among all culture positive cases mono microbial growth were 144 (94.12%) and poly microbial growth were 9 (5.88%) which were supported by a couple of original researches.^{27,28} Higher prevalence of gram negative organisms also showed similarity with several articles.²⁹⁻³³ *E. coli* were found to be the most predominant bacteria (60.49%) both in the present study and others supporting the hypothesis that *E. coli* have an adherence factor called P fimbriae or pilli, hemolysin, mannose resistant fimbria, siderophore and P-1 blood group phenotype receptor which mediate the attachment of *E. coli* to uroepithelial cells.^{34,36-38} *E. coli* showed high resistance to commonly used β -lactam antibiotics such as Amoxiclav, indicating extended-spectrum beta-lactamase (ESBL) production. Carbapenems (Imipenem and Meropenem) remain the most

effective choices for treating infections caused by this pathogen.^{12,39,40} In present study, higher rate of resistance exhibited by *E. coli* towards amoxiclav, cotrimoxazole and ciprofloxacin, 77.55%, 71.43% and 56.12% respectively. Near similar observations were also true for several studies.⁴¹⁻⁴³ Fosfomycin showed the highest sensitivity to highest number of organisms. Fosfomycin showed high level of susceptibility against all of the uropathogens. 100% susceptibility was seen for *Proteus spp.*, *Enterobacter*, *S. aureus* and *Enterococci*. *E. coli* only had 2 instances of resistance. Highest susceptibility towards Fosfomycin for almost all organism is found invariably in multiple literatures also.⁴⁴⁻⁴⁹ The cross-sectional nature of the study is the limitation of the present study. This study has no conflict of interest among the involved parties.

CONCLUSION

E. coli was the most prevalent bacterial isolate and exhibited high resistance to commonly used antibiotics like Amoxiclav, Ciprofloxacin, and Ceftriaxone. Carbapenems and Fosfomycin remained effective. *Klebsiella spp.* and *Pseudomonas spp.* showed resistance to cephalosporins but were highly sensitive to carbapenems and aminoglycosides. Gram-positive organisms (*Staphylococcus aureus*, CoNS, and *Enterococcus*) showed high sensitivity to Vancomycin and Linezolid, confirming the importance of these drugs in treating resistant Gram-positive infections. Fosfomycin resistance was minimal, reinforcing its role in treating multidrug-resistant UTIs.

Funding: No funding sources.

Conflict of Interests: None declared.

REFERENCES

1. Chiu CC, Lin TC, Wu RX, Yang YS, Hsiao PJ, Lee Y, et al. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms. *J Microbiol Immunol Infect.* 2017 Dec;50(6):879–85.
2. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol.* 2015 May;13(5):269–84.
3. Gajdacs M, Urbán E. Resistance Trends and Epidemiology of Citrobacter-Enterobacter-Serratia in Urinary Tract Infections of Inpatients and Outpatients (RECESUTI): A 10-Year Survey. *Medicina (Mex).* 2019 Jun 18;55(6):285.
4. Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. *Front Public Health.* 2022 Jul 27; 10:888205.
5. Rustom S, Zaman RF, Barua P, Khanum H. Urinary tract infection among the outpatients of a diagnostic center in Dhaka, Bangladesh. *Bangladesh J Zool.* 2021 Apr 11;48(2):347–56.
6. Pradeshi P. Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI. *Indian J Microbiol Res.* 2020 Dec 28;5(3):334–8.
7. Kibret M, Abera B. Prevalence and antibiogram of bacterial isolates from urinary tract infections at Dessie Health Research Laboratory, Ethiopia. *Asian Pac J Trop Biomed.* 2014 Feb;4(2):164–8.
8. Modi PS, Kumar A, Jethava SD, Sanghavi RR. BACTERIAL PREVALENCE, ANTIBIOTIC SENSITIVITY PATTERN AND PREDISPOSING FACTORS IN PATIENTS OF NOSOCOMIAL URINARY TRACT INFECTION (UTI) VISITED THE TERTIARY CARE HOSPITAL IN JAMNAGAR REGION, WESTERN GUJARAT, INDIA. *J Evid Based Med Healthc.* 2017 Aug 3;4(62):3746–51.
9. Adugna B, Sharew B, Jemal M. Bacterial Profile, Antimicrobial Susceptibility Pattern, and Associated Factors of Community- and Hospital-Acquired Urinary Tract Infection at Dessie Referral Hospital, Dessie, Northeast Ethiopia. Falkinham J, editor. *Int J Microbiol.* 2021 Sep 18; 2021:1–14.
10. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob.* 2007 Jan;6(1):4.
11. Rahman S, Ahmed M, Begum A. Occurrence of Urinary Tract Infection in Adolescent and Adult Women of Shanty Town in Dhaka City, Bangladesh. *Ethiop J Health Sci.* 2014 Apr 14;24(2):145.
12. Kumar H, Singh VA, Nagpal S, Biswas D. Isolation of Uropathogens And Their Antibiotic Susceptibility Pattern At A Tertiary Care Hospital In Northern India. *Asian J Pharm Clin Res.* 2019 Oct 23;84–6.
13. Abubakar EMM. Antimicrobial susceptibility pattern of pathogenic bacteria causing urinary

- tract infections at the Specialist Hospital, Yola, Adamawa state, Nigeria. *J Clin Med Res*. 2009;1(1):1–8.
14. World Health Organization. Antimicrobial resistance: global report on surveillance [Internet]. Geneva: World Health Organization; 2014.
 15. Eshwarappa M, Dosegowda R, Aprameya Iv, Khan M, Kumar Ps, Kempegowda P. Clinico-microbiological profile of urinary tract infection in South India. *Indian J Nephrol*. 2011;21(1):30.
 16. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK. 'Phosphonomycin, a new antibiotic produced by strains of streptomyces. 1969;122–3.
 17. Johnson JR, Drawz SM, Porter S, Kuskowski MA. Susceptibility to Alternative Oral Antimicrobial Agents in Relation to Sequence Type ST131 Status and Coresistance Phenotype among Recent *Escherichia coli* Isolates from U.S. Veterans. *Antimicrob Agents Chemother*. 2013 Oct;57(10):4856–60.
 18. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. *Antimicrob Resist Infect Control*. 2017 Dec;6(1):47.
 19. Subedi N, Pudasaini S. Bacteriological profile and antibiotic sensitivity pattern in patients with Urinary tract infection. *J Pathol Nepal*. 2017 Mar 30;7(1):1066–9.
 20. Almukhtar SH. Urinary Tract Infection Among Women Aged (18-40) Years Old in Kirkuk City, Iraq. *Open Nurs J*. 2018 Dec 31;12(1):248–54.
 21. Sanjee SA, Karim ME, Akter T, Parvez MAK, Hossain M, Jannat B, et al. Prevalence and Antibigram of Bacterial Uropathogens of Urinary Tract Infections from a Tertiary Care Hospital of Bangladesh. *J Sci Res*. 2017 Sep 1;9(3):317–28.
 22. Mahmood N, Siddiqui MR, Giasuddin RS, Islam M, Siddiqui MNKK. Recurrent Urinary Tract Infection- Etiology, Risk Factors and Outcome in a Tertiary Care Hospital of Bangladesh. *Bangladesh J Med*. 2024 Sep 30;35(3):173–9.
 23. Rustom S, Zaman RF, Barua P, Khanum H. Urinary tract infection among the outpatients of a diagnostic center in Dhaka, Bangladesh. *Bangladesh J Zool*. 2021 Apr 11;48(2):347–56.
 24. Odoki M, Almustapha Aliero A, Tibyangye J, Nyabayo Maniga J, Wampande E, Drago Kato C, et al. Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda. *Int J Microbiol*. 2019 Feb 17;2019:1–8.
 25. Christy Vr, Athinarayanan G, Mariselvam R, Dhasarathan P, Singh Raja. Epidemiology of urinary tract infection in south India. *Biomed Res Clin Pract*. 2019 [cited 2025 Feb 16];4(3). <https://www.oatext.com/epidemiology-of-urinary-tract-infection-in-south-india.php>
 26. Ahmed AE, Abdelkarim S, Zenida M, Baiti MAH, Alhazmi AAY, Alfaifi BAH, et al. Prevalence and Associated Risk Factors of Urinary Tract Infection among Diabetic Patients: A Cross-Sectional Study. *Healthcare*. 2023 Mar 15;11(6):861.
 27. Haque R, Akter MostL, Salam MdA. Prevalence and susceptibility of uropathogens: a recent report from a teaching hospital in Bangladesh. *BMC Res Notes*. 2015 Dec;8(1):416.
 28. Perry JD. Evaluation of a new chromogenic medium, Uriselect 4, for the isolation and identification of urinary tract pathogens. *J Clin Pathol*. 2003 Jul 1;56(7):528–31.
 29. Bhargava D, Bijay Raj P, Amarullah S, Ravi Shankar G. Bacterial Uropathogens and their Antibiotic Sensitivity Pattern at a Tertiary Care Hospital in Birgunj, Nepal. *Med Phoenix*. 2017 Oct 13;2(1):74–7.
 30. Fenta A, Dagnew M, Eshetie S, Belachew T. Bacterial profile, antibiotic susceptibility pattern and associated risk factors of urinary tract infection among clinically suspected children attending at Felege-Hiwot comprehensive and specialized hospital, Northwest Ethiopia. A prospective study. *BMC Infect Dis*. 2020 Dec;20(1):673.
 31. Nedbal C, Mahobia N, Browning D, Somani BK. Gram negative bacteria related urinary tract infections: spectrum of antimicrobial resistance over 9 years in a university tertiary referral Hospital. *Ther Adv Infect Dis*. 2024 Jan; 11:20499361241228342.
 32. Imran Qadir M, Idrees MM. Urinary Tract Infection: An Infection Caused by Gram-Negative Bacteria especially *E. coli*. In: Imran Qadir M, editor. *Bacterial Diseases*. BENTHAM SCIENCE PUBLISHERS; 2020 [cited 2025 Feb 16]. p. 176–9. <https://www.eurekaselect.com/node/185741>
 33. Khoshnood S, Heidary M, Mirnejad R, Bahramian A, Sedighi M, Mirzaei H. Drug-resistant gram-negative uropathogens: A review. *Biomed Pharmacother*. 2017 Oct;94:982–94.

34. Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y, et al. Urinary Tract Infections Caused by Uropathogenic *Escherichia coli*: Mechanisms of Infection and Treatment Options. *Int J Mol Sci*. 2023 Jun 23;24(13):10537.
35. Lee DS, Lee SJ, Choe HS. Community-Acquired Urinary Tract Infection by *Escherichia coli* in the Era of Antibiotic Resistance. *BioMed Res Int*. 2018 Sep 26;2018:1–14.
36. Al Nafeesah A, Al Fakeeh K, Chishti S, Hameed T. *E. coli* versus Non-*E. coli* Urinary Tract Infections in Children: A Study from a Large Tertiary Care Center in Saudi Arabia. *Int J Pediatr Adolesc Med*. 2022 Mar;9(1):46–8.
37. Odongo I, Ssemambo R, Kungu JM. Prevalence of *Escherichia Coli* and Its Antimicrobial Susceptibility Profiles among Patients with UTI at Mulago Hospital, Kampala, Uganda. *Interdiscip Perspect Infect Dis*. 2020 Feb 1;2020:1–5.
38. Shah C, Baral R, Bartaula B, Shrestha LB. Virulence factors of uropathogenic *Escherichia coli* (UPEC) and correlation with antimicrobial resistance. *BMC Microbiol*. 2019 Dec;19(1):204.
39. Chowdhury S, Parial R. Antibiotic Susceptibility Patterns of Bacteria among Urinary Tract Infection Patients in Chittagong, Bangladesh. *SMU*. 2015;2(1).
40. Siddiqua M, Alam AN, Akter S, Ferdousi RS. Antibiotic resistance pattern of bacteria causing urinary tract infection in a private medical college hospital, Dhaka. *Bangladesh J Med Sci*. 2017 Jan 16;16(1):42–7.
41. Islam MA, Islam MR, Khan R, Amin MB, Rahman M, Hossain MI, et al. Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections in Dhaka, Bangladesh. Bhatta DR, editor. *PLOS ONE*. 2022 Sep 15;17(9): e0274423.
42. Setu SK, Sattar ANI, Saleh AA, Roy CK, Ahmed M, Muhammadullah S, et al. Study of Bacterial pathogens in Urinary Tract Infection and their antibiotic resistance profile in a tertiary care hospital of Bangladesh. *Bangladesh J Med Microbiol*. 2017 Feb 13;10(1):22–6.
43. Patel H, Soni S, Bhagyalaxmi A, Patel N. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. *J Fam Med Prim Care*. 2019;8(1):154.
44. Banerjee S, Sengupta M, Sarker T. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. *Indian J Urol*. 2017;33(2):149.
45. Rajenderan S, Balaji V, Anandan S, Sahni RD, Tansarli GS, Falagas ME. Determination of MIC Distribution of Arbekacin, Cefminox, Fosfomycin, Biapenem and Other Antibiotics against Gram-Negative Clinical Isolates in South India: A Prospective Study. Van Schaik W, editor. *PLoS ONE*. 2014 Jul 28;9(7):e103253.
46. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of Urinary Tract Bacteria to Fosfomycin. *Antimicrob Agents Chemother*. 2009 Oct;53(10):4508–10.
47. Sabharwal ER. Fosfomycin: An Alternative Therapy for the Treatment of UTI Amidst Escalating Antimicrobial Resistance. *J Clin Diagn Res*. 2015;9(12).
48. Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM. SUSceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. *Int J Antimicrob Agents*. 2022 May;59(5):106574.
49. Sharmin S, Kamal SMM, Reza MdA, Elahi KMA, Elma SMM, Habib B. Fosfomycin—A Promising Oral Antibiotic for the Treatment of Urinary Tract Infection (UTI). *Open J Urol*. 2022;12(05):257–70

*Correspondence: Dr. Shamima Nasrin, Email: shamima.16djmc@gmail.com

Journal of Teachers Association
Official Journal of Teachers Association
Rajshahi Medical College



Publish your next article in TAJ
For submission scan the QR code
E-mail submission to: tajrmc8555@gmail.com